DISCOVER

Vascepa

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.

recent news


28 Jun 2018

Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study MORE

25 Jun 2018

Real-World Data Supports Association Between High Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs in People with Diabetes Mellitus MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
2.80
Change:
+0.03
Date:
4:00 PM EDT on Jul 20, 2018
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe